(19)
(11) EP 4 297 738 A1

(12)

(43) Date of publication:
03.01.2024 Bulletin 2024/01

(21) Application number: 22707819.3

(22) Date of filing: 22.02.2022
(51) International Patent Classification (IPC): 
A61K 31/05(2006.01)
A61P 25/08(2006.01)
A61K 31/551(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/05; A61K 31/551; A61P 25/08
 
C-Sets:
  1. A61K 31/05, A61K 2300/00;
  2. A61K 31/551, A61K 2300/00;

(86) International application number:
PCT/GB2022/050476
(87) International publication number:
WO 2022/180379 (01.09.2022 Gazette 2022/35)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 25.02.2021 GB 202102694

(71) Applicant: GW Research Limited
Cambridge, Cambridgeshire CB24 9BZ (GB)

(72) Inventors:
  • KNAPPERTZ, Volker Armin
    Carlsbad, CA 92008 (US)
  • CHECKETTS, Daniel Adam
    Cambridge Cambridgeshire CB24 9BZ (GB)

(74) Representative: HGF 
HGF Limited 1 City Walk
Leeds LS11 9DX
Leeds LS11 9DX (GB)

   


(54) USE OF CANNABIDIOL AND CLOBAZAM IN THE TREATMENT OF CHILDHOOD-ONSET EPILEPSY SYNDROMES